ABLYNX SUCCESSFULLY RAISES ?31.5 MILLION, IN TOTAL ?45 MILLION PLACED
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 28 February 2013 - Ablynx [Euronext Brussels: ABLX], the
biopharmaceutical company focused on the discovery and development of
Nanobodies®, announces today that it has raised ?31.5 million through a private
placement of new shares via an accelerated bookbuilding procedure announced on
Wednesday 27 February 2013 after the market closed.
The private placement has allowed Ablynx to place 4,377,919 new shares with a
range of domestic and international institutional investors and qualified
institutional buyers in the United States at a price of ?7.2 per share, a 6.7%
discount on the previous closing price. This represents 10.0% of the current
number of outstanding shares and will bring the total number of shares after the
issue to 48,157,116. The new shares will be admitted to trading on NYSE Euronext
Brussels following their issuance, which is expected to take place on 5 March
2013.
The private placement was oversubscribed and certain pre-IPO shareholders and
warrant holders sold 1,872,081 shares at the same price in conjunction with this
transaction.
The funds will be used by Ablynx to:
* maintain the momentum of ALX-0061 and review paths (e.g. co-development,
fund additional clinical trials, retain (co-) promotion rights) which could
allow the value of this asset to be maximized;
* allow flexibility in the structure and timing of any potential deals to
license clinical assets such as caplacizumab (anti-vWF) and ALX-0171 (anti-
RSV);
* initiate, advance and/or accelerate the pre-clinical development for wholly-
and co-owned programmes with a broad range of risk-return profiles; and
* for general corporate purposes.
KBC Securities NV acted as Global Coordinator. KBC Securities NV, Bryan, Garnier
& Co. Limited and Nomura Code Securities Limited acted as Joint Bookrunners for
the placement.
Dr Edwin Moses, Chairman and CEO of Ablynx commented:
"We are very pleased to announce the successful completion of the private
placement which we believe reflects the strong progress made at Ablynx over the
past year. The new funds will give us increased flexibility to invest in our
Nanobody pipeline and in particular to build on the successful Phase II results
of our rheumatoid arthritis product, ALX-0061, announced earlier this month. We
are grateful to our existing shareholders for their continuing support and
welcome our new investors. We believe that Ablynx is well placed to deliver
significant value to shareholders in the coming years and we look forward to
updating them on our progress during 2013."
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and five Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and significant
partnerships with major pharmaceutical companies including Boehringer Ingelheim,
Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent,
Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx(at)mcomgroup.com
Press release in pdf format:
http://hugin.info/137912/R/1682073/550116.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1682073]
Unternehmensinformation / Kurzprofil:
Datum: 28.02.2013 - 15:09 Uhr
Sprache: Deutsch
News-ID 234553
Anzahl Zeichen: 5035
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX SUCCESSFULLY RAISES ?31.5 MILLION, IN TOTAL ?45 MILLION PLACED"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
